Commitments and Contingencies - Licenses (Details) $ in Millions |
1 Months Ended | 12 Months Ended | |
|---|---|---|---|
|
Mar. 31, 2015
USD ($)
person
|
Dec. 31, 2015
USD ($)
|
Dec. 31, 2014 |
|
| Allergan | |||
| Collaboration Revenue. | |||
| Payment received to fund expansion of clinical trial | $ 10.0 | ||
| Number of patients before expansion of the trial | person | 500 | ||
| Number of patients after expansion of the trial | person | 620 | ||
| Option agreement and a license agreement | Minimum | |||
| Collaboration Revenue. | |||
| Tiered royalties that could be received, as a percentage of net sales of licensed products | 10.00% | ||
| Option agreement and a license agreement | Maximum | |||
| Collaboration Revenue. | |||
| Tiered royalties that could be received, as a percentage of net sales of licensed products | 20.00% | ||
| Option agreement and a license agreement | Allergan | |||
| Collaboration Revenue. | |||
| Consideration received upon the grant of the option | $ 0.0 | ||
| Aggregate potential consideration | 365.0 | ||
| Option exercise fee | $ 65.0 | ||
| Term of royalty on sales from the first commercial sale of product | 10 years | ||
| X | ||||||||||
- Definition Represents the consideration received by the reporting entity upon grant of option to the counterparty under the agreement. No definition available.
|
| X | ||||||||||
- Definition Describes the maximum potential amount of consideration, undiscounted, which could be received under the agreement. No definition available.
|
| X | ||||||||||
- Definition Represents the payment received to fund the expansion of a clinical trial. No definition available.
|
| X | ||||||||||
- Definition Represents the term of royalty on sales receivable by the entity starting from the first commercial sale effected of the licensed product under the agreement. No definition available.
|
| X | ||||||||||
- Definition Represents the tiered royalty that could be received, expressed as a percentage of net sales of licensed products. No definition available.
|
| X | ||||||||||
- Definition Represents the upfront option exercise fee included in the potential consideration. No definition available.
|
| X | ||||||||||
- Definition Represents the number of patients after the expansion of the trial. No definition available.
|
| X | ||||||||||
- Definition Represents the number of patients before the expansion of the trial. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|